ERCC1 as a Biomarker for Bladder Cancer Patients Likely to Benefit From Adjuvant Chemotherapy

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-12-187
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Mp58-07 Use of Adjuvant Chemotherapy in Patients With Advanced Bladder Cancer After Neoadjuvant Chemotherapy

Journal of Urology
Urology
2017English

Adjuvant Chemotherapy Versus Observation After Radical Cystectomy in Patients With Node-Positive Bladder Cancer

Scientific Reports
Multidisciplinary
2019English

P1.16-12 Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit From Adjuvant Chemotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Correlations Between Microsatellite Instability, ERCC1/XRCC1 Polymorphism and Clinical Characteristics, and FOLFOX Adjuvant Chemotherapy Effect of Colorectal Cancer Patients

Cancer genetics
Cancer ResearchGeneticsMolecular Biology
2017English

Pd15-09 Neoadjuvant vs Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Propensity Matched Analysis

Journal of Urology
Urology
2018English

Mismatch Repair Status in the Prediction of Benefit From Adjuvant Fluorouracil Chemotherapy in Colorectal Cancer

Gut
Gastroenterology
2006English

Correlation of ERCC1 Expression in Peripheral Blood Lymphocytes With Outcomes of Patients With Gastric Cancer Treated With Oxaliplatin-Based Adjuvant Chemotherapy

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2015English

Role of Progranulin Gene Expression as a Molecular Biomarker for Bladder Cancer

American Journal of Biochemistry and Biotechnology
BiochemistryBiotechnology
2012English

A Novel Biomarker for Diagnosis of Bladder Cancer

Folia Pharmacologica Japonica
Pharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy